[Skip to Content]

Claim CME

Fungal Infections

Prophylaxis Against Pneumocystis jirovecii Pneumonia in Adults

To identify the key insights or developments described in this article

1 Credit CME

JAMA

Published Online: June 26, 2023

JAMA Insights

Article Information and Disclosures

Shiwei Zhou, MD¹;

Samuel L. Aitken, PharmD, MPH²

Author Affiliations

¹Department of Internal Medicine, Division of Infectious Diseases, Michigan Medicine, Ann Arbor
²Department of Pharmacy, Michigan Medicine, Ann Arbor

Read article on JAMA Network

Read Article Claim CME

Pneumocystis jirovecii is an opportunistic fungal pathogen that causes life-threatening pneumonia in immunocompromised patients. Patients with Pneumocystis pneumonia (PCP) typically present with fever, nonproductive cough, dyspnea, and hypoxemia with diffuse bilateral ground-glass opacities on chest imaging.¹ PCP can be prevented by reducing immunosuppression and with chemoprophylaxis. Effective prophylaxis significantly decreases the incidence of infection.² This article summarizes current recommendations regarding prevention of PCP in patients who are immunocompromised.³^- 5

Claim CME

Sign in to take quiz and track your certificates

Buy This Activity

Article Information

Corresponding Author: Shiwei Zhou, MD, Michigan Medicine, University of Michigan, 1500 E Medical Center Dr, Ann Arbor, MI 48109 (shzh@med.umich.edu).

Published Online: June 26, 2023. doi:10.1001/jama.2023.9844

Correction: This article was corrected on September 13, 2023, to correct typographical errors in the Table.

Conflict of Interest Disclosures: Dr Aitken reported receiving personal fees from bioMerieux, F2G, Entasis, Shionogi, GSK, Melinta, AstraZeneca, Enstasis, and Basilea outside the submitted work. No other disclosures were reported.

References

Apostolopoulou A , Fishman JA . The pathogenesis and diagnosis of pneumocystis jiroveci pneumonia. J Fungi (Basel). 2022;8(11):1167. doi:10.3390/jof8111167 PubMed Google Scholar Crossref

Trubin PA , Azar MM . Current concepts in the diagnosis and management of pneumocystis pneumonia in solid organ transplantation. Infect Dis Clin North Am. Published May 2, 2023. doi:10.1016/j.idc.2023.03.005 PubMed Google Scholar Crossref

Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. National Institutes of Health, Centers for Disease Control and Prevention, HIV Medicine Association, and Infectious Diseases Society of America; 2023.

Gandhi RT , Bedimo R , Hoy JF , et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the International Antiviral Society-USA Panel. JAMA. 2023;329(1):63-84. doi:10.1001/jama.2022.22246 PubMed Google Scholar Crossref

Baden LR , Swaminathan S , Angarone M , et al. Prevention and treatment of cancer-related infections, version 2.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016;14(7):882-913. doi:10.6004/jnccn.2016.0093 PubMed Google Scholar Crossref

Fishman JA , Gans H , Infectious Diseases AST ; AST Infectious Diseases Community of Practice. Pneumocystis jiroveci in solid organ transplantation: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33(9):e13587. doi:10.1111/ctr.13587 PubMed Google Scholar Crossref

Taplitz RA , Kennedy EB , Bow EJ , et al. Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA Clinical Practice Guideline Update. J Clin Oncol. 2018;36(30):3043-3054. doi:10.1200/JCO.18.00374 PubMed Google Scholar Crossref

Wolfe RM , Peacock JE Jr . Pneumocystis pneumonia and the rheumatologist: which patients are at risk and how can PCP be prevented? Curr Rheumatol Rep. 2017;19(6):35. doi:10.1007/s11926-017-0664-6 PubMed Google Scholar Crossref

Maschmeyer G , De Greef J , Mellinghoff SC , et al; European Conference on Infections in Leukemia (ECIL). Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology: a position paper by the European Conference on Infections in Leukemia (ECIL). Leukemia. 2019;33(4):844-862. doi:10.1038/s41375-019-0388-x PubMed Google Scholar Crossref

Redelman-Sidi G , Michielin O , Cervera C , et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies. Clin Microbiol Infect. 2018;24(suppl 2):S95-S107. doi:10.1016/j.cmi.2018.01.030 Google Scholar Crossref

AMA CME Accreditation Information

Credit Designation Statement: The American Medical Association designates this Journal-based CME activity activity for a maximum of 1.00  AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:

1.00 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program;;
1.00 Self-Assessment points in the American Board of Otolaryngology – Head and Neck Surgery’s (ABOHNS) Continuing Certification program;
1.00 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program;
1.00 Lifelong Learning points in the American Board of Pathology’s (ABPath) Continuing Certification program; and
1.00 credit toward the CME of the American Board of Surgery’s Continuous Certification program

It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting MOC credit.